197
Registered trials
75
Recruiting
102
Completed trials
90
Sponsors
27
Countries
Phase III:
89
Phase II/III:
8
Phase II:
63
Phase I/II:
19
Phase III/IV:
4
Phase IV:
8
Phase I:
2
Phase I (FiH):
4
Oversight events:
6 serious breaches
95 temporary halts
12 urgent safety measures
7 unexpected events
11 corrective measures
across 31 trials
View oversight register →
Indications tested
Plasma cell myeloma
6
Plasma cell myeloma refractory
4
Non-small cell lung cancer
3
Diffuse large B-cell lymphoma
3
Prostate cancer metastatic
3
Dermatomyositis
2
Polymyositis
2
Relapsing multiple sclerosis
2
Diffuse large B-cell lymphoma stage II
1
Endolymphatic hydrops
1
Hormone receptor positive breast cancer
1
Injection site pain
1
Sponsors using this IMP
Janssen - Cilag International
13
Celgene Corp.
12
Pfizer Inc.
10
Sanofi-Aventis Recherche & Developpement
9
Regeneron Pharmaceuticals Inc.
8
European Myeloma Network B.V.
7
Fundacion PETHEMA
7
AbbVie Deutschland GmbH & Co. KG
6
Amgen Inc.
6
Emn Trial Office S.r.l. Impresa Sociale
6
Glaxosmithkline Research & Development Limited
6
Hellenic Society Of Hematology
6
All trials
197 totalShowing 1–24 of 197 trials